VIDEO: Addressing manufacturing, production time challenges of CAR T-cell therapy

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The key issues that we’ve seen with the initial FDA approval of both ide-cel and cilta-cel were limitations on the number of patients who can get apheresed on a monthly basis, so there were manufacturing slot issues. And then the production time was taking longer than anticipated — longer than 4 weeks. So both of these challenges early on appear to be overcome. We have more slot availability and better vein-to-vein time, compared to that early experience. But in my experience, it’s still not the same as what was initially reported in trials. And then we also have to think about them out of specification products — so products that we are getting with either some logistic or specific manufacturing out of specifications, or lower number of overall CAR cells being manufactured that we have to give to patients because of that. So, I'm hoping that some of these challenges do continue to get better over time and the quality of products also improves.